Bufalin Inhibits the Proliferation of Human Esophageal Carcinoma TE13 Cells through Down-regulation of ERK
Keywords:
Esophageal carcinoma, bufalin, ERKAbstract
The purpose of this study was to investigate the effect of bufalin on the proliferation in the human esophageal carcinoma cell lines TE13 and to determine the relevant molecular mechanism. Bufalin could be a useful agent as a novel antitumor agent to inhibit carcinoma cell proliferation through down-regulate ERK. The immunocytochemistry and western blotting analysis were applied to measure the levels of ERK in bufalin-treated TE13 cells. The results indicated that bufalin inhibited the phosphorylation of ERK. The cytometry and MTT assays showed that proliferation effects were inhibited especially in bufalin-treated esophageal carcinoma TE13 cells. Taken together, the results of the research confirmed that bufalin produced the anti-proliferative effect on TE13 cells by contributing to the down-regulation of ERK.
References
Shiratori O (1967) Growth inhibitory effect of cardiac glycosides and aglycones on neoplastic cells: in vitro and in vivo studies. Gann 58:521–528
Takai N, Ueda T, Nishida M et al (2008) Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med 21:637–643
Mijatovic T, Roland I, Van Quaquebeke E et al (2007) The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol 212:170–179
Yeh JY, Huang WJ, Kan SF et al (2003) Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54:112–124
Newman RA, Kondo Y, Yokoyama T et al (2007) Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther 6:354–364
Takai N, Kira N, Ishii T, et al: Bufalin, a traditional oriental medicine, induces apoptosis in human cancer cells. Asian Pac J Cancer Prev 13: 399-402, 2012.
Krenn L and Kopp B: Bufadienolides from animal and plant sources. Phytochemistry 48: 1-29, 1998.
Yu CH, Kan SF, Pu HF, Jea Chien E and Wang PS: Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci 99: 2467-2476, 2008.
Qi, F.; Inagaki, Y.; Gao, B.; Cui, X.; Xu, H.; Kokudo, N.; Li, A.; Tang, W. Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci. 2011, 102, 951–958.
Chen, A.; Yu, J.; Zhang, L.; Sun, Y.; Zhang, Y.; Guo, H.; Zhou, Y.; Mitchelson, K.; Cheng, J. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. Biotechnol. Lett. 2009, 31, 487–494.
Takai, N.; Ueda, T.; Nishida, M.; Nasu, K.; Narahara, H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int. J. Mol. Med. 2008, 21, 637–643.
Xie, C.M.; Chan, W.Y.; Yu, S.; Zhao, J.; Cheng, C.H. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic. Biol. Med. 2011, 51, 1365–1375.
Mendes O, Kim HT, Lungu G, Stoica G. 2007. MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metastasis 24:341–351.
Huang WW, Yang JS, Pai SJ, et al: Bufalin induces G(0)/G(1) phase arrest through inhibiting the levels of cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells. Mutat Res 732: 26-33, 2012.
Masuda Y, Kawazoe N, Nakajo S, Yoshida T, Kuroiwa Y and Nakaya K: Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk Res 19: 549-556, 1995.
Qi F, Inagaki Y, Gao B, et al: Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci 102: 951-958, 2011.
Han KQ, Huang G, Gu W, Su YH, Huang XQ and Ling CQ: Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenterol 13: 3374-3379, 2007.
Yu CH, Kan SF, Pu HF, Jea Chien E, Wang PS. Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent fgCM,
Chan WY, Yu S, Zhao J, Cheng CH. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med. 2011;51(7):1365–75.
Chen Y, Guo Q, Zhang B, Kang M, Xie Q, Wu Y. Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. Oncol Lett. 2012;4(4):792–8.
Tsai SC, Yang JS, Peng SF, Lu CC, Chiang JH, Chung JG, et al. Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells. Int J Oncol. 2012.
Downloads
Published
Issue
Section
License
- Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
- It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
- The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
- The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.
